Value through Innovation

main navigation

jump to content to meta navigation
Headillu

page content

jump to main navigation to meta navigation

Boehringer Ingelheim Press Releases

See the latest Boehringer Ingelheim news releases. To quickly find all news releases on a specific topic, please use the fulltext search.

Press Release Archive

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
30.08.2009 Groundbreaking results in the RE-LY® trial - novel oral direct thrombin inhibitor dabigatran etexilate convincingly beats warfarin - superior stroke reduction with less bleeding! - For medical media, outside the US and the UK only
28.08.2009 Data from largest GOLD Stage II patient population treated with tiotropium highlight the benefits of earlier treatment of COPD - For medical media, outside the US only
03.08.2009 Boehringer Ingelheim to commence Phase III study investigating the role of BIBW 2992 as first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR mutations
28.07.2009 Good first six months in 2009 for Boehringer Ingelheim - Successful products Spiriva®, Micardis® and Flomax® secure good growth
22.07.2009 Head-to-head trial demonstrates Viramune®’s similar efficacy and more favourable effect on lipid profile compared to atazanavir/ritonavir - For medical media, outside the US only
09.07.2009 Successful promissory note (Schuldschein) placement
06.07.2009 European Commission approves statement on lipid improvement for Viramune® label - For medical media, outside the US only
26.06.2009 Boehringer Ingelheim receives positive recommendation from European scientific committee for a new once daily Mirapexin (pramipexole) formulation for the treatment of Parkinson`s disease - For medical media, outside the US only
22.06.2009 Expedition to Mount Everest offers new insights into chronic disease - For medical media, outside the US only
15.06.2009 Boehringer Ingelheim and Vitae Pharmaceuticals announce a major collaboration to research and develop novel treatments for Alzheimer`s disease
14.06.2009 New investigational combination telmisartan and amlodipine shows effective and well-tolerated 24-hour blood pressure control in hypertensive patients at risk of cardiovascular events - For medical media, outside the US only
10.06.2009 New data once more show high therapeutic benefits of Boehringer Ingelheim`s Mirapexin®/Sifrol® (pramipexole) once-daily extended release formulation, also in patients with advanced Parkinson`s disease - For medical media, outside the US only
06.06.2009 New data from Boehringer Ingelheim`s ongoing linagliptin trial programme show promising safety and efficacy results - For medical media, outside the US only
29.05.2009 Boehringer Ingelheim and DxS sign an agreement for a companion diagnostic to identify EGFR mutations in patients with lung cancer
27.05.2009 Boehringer Ingelheim and the World Stroke Organization announce partnership in the World Stroke Academy - For medical media, outside the US only
15.05.2009 Boehringer Ingelheim to present new phase II clinical data on two lead oncology compounds at ASCO 2009 - For medical media, outside the US only
13.05.2009 Boehringer Ingelheim and DeveloGen AG announce agreement in the field of diabetes, obesity and the metabolic syndrome
08.05.2009 Exelixis and Boehringer Ingelheim enter into collaboration for development of S1P1 receptor agonists in the field of autoimmune diseases
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
back to top

Contact

Boehringer Ingelheim GmbH

Corporate Headquarters
Binger Str. 173
55216 Ingelheim
Germany


Phone +49 / 6132 / 77 0
Fax +49 / 6132 / 72 0

media contacts

RSS feeds allow you to receive latest news and information about Boehringer Ingelheim.

subscribe to RSS Feed